Home
Resources
Diseases
Compendium
Training
Evaluation
The Tool
The Tutorial
SYSVAC
About
Registry
E-learning courses
News
Webinars
Network
Steering Committee
Vision and Mission
Map
Meetings
Partners
Join us
Home
Resources
Resources
Type of publications
Guidelines (30)
NITAG documentation (1591)
Reports (55)
SAGE documentation (218)
Scientific publications (112)
Systematic reviews (SYSVAC) (2750)
Regions
Africa (267)
Americas (762)
Eastern Mediterranean (48)
Europe (704)
South-East Asia (78)
Western Pacific (196)
Diseases
Chikungunya (9)
Cholera (33)
COVID-19 (1481)
Cytomegalovirus (1)
Dengue (39)
Diphtheria (79)
Ebola (16)
Escherichia coli (ETEC) (2)
Haemophilus influenzae type B (66)
Hepatitis A (63)
Hepatitis B (153)
Hepatitis C (4)
Hepatitis E (5)
Herpes simplex (1)
Herpes zoster (66)
HIV / AIDS (10)
Human papillomavirus (HPV) (472)
Influenza (573)
Japanese encephalitis (34)
Lyme disease, Borreliosis (1)
Malaria (27)
Measles (128)
Meningococcal disease (145)
Mpox (55)
Mumps (46)
Pertussis (104)
Pneumococcal disease (266)
Poliomyelitis (84)
Q fever (1)
Rabies (28)
Rotavirus (115)
RSV (Respiratory syncytial virus) (47)
Rubella (64)
Salmonella (2)
Shigella (1)
Smallpox (16)
Streptococcus group B (6)
Tetanus (59)
Tick-borne encephalitis (12)
Tuberculosis (73)
Typhoid (23)
Varicella (69)
Yellow fever (42)
Zika (1)
Show more
4756 results found
2015
∙
SAGE
Efficacy of a single-dose MenA conjugate vaccination in immunocompetent children (9 to 24 months of age) against serogroup A meningococcal disease
2015
∙
SAGE
Efficacy of a two dose schedule of MenA conjugate vaccination in immunocompetent children (3 to 9 months of age) against serogroup A meningococcal disease
2015
∙
CoNaIn
National Immunization Schedule (Argentina)
2015
∙
SAGE
Pertussis Vaccine Evidence to Recommendations Table
2015
∙
SAGE
Protective Efficacy/Effectiveness of Whole Cell Pertussis Vaccines (wP) in Immunocompetent Infants and Children
2015
∙
SAGE
Safety of MenA conjugate vaccination in immunocompetent children (3 to 24 months of age)
2015
∙
OFSP
Swiss 2015 vaccination plan
2015
∙
SAGE
What is the risk of serious adverse events following vaccination with live attenuated JE vaccine?
2015
∙
SAGE
What is the risk of serious adverse events following vaccination with live recombinant JE vaccine?
2015
∙
PTAC Immunisation subcommittee
2014-09 immunisation subcommittee minutes
Home
Resources
Diseases
Compendium
Training
Evaluation
SYSVAC
News
Webinars
Network
Sign in / Register